The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
January 2, 2020
Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading
December 16, 2019
The Quarterly Performance Report for the first quarter of the 2019-2020 fiscal year is now available online. Continue reading